We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical tri... Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development. Show more
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 3) (Rule 13e-4) Tender Offer Statement Under...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 2) (Rule 13e-4) Tender Offer Statement Under...
As filed with the Securities and Exchange Commission on February 14, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
0001597553FYfalsehttp://fasb.org/us-gaap/2023#RelatedPartyMemberhttp://fasb.org/us-gaap/2023#RelatedPartyMemberP1YP1Ytruehttp://fasb.org/us-gaap/2023#DomesticPlanMemberhttp://fasb.org/us-gaap/2023...
DE false 0001597553 0001597553 2024-02-14 2024-02-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.075 | -5.46239837398 | 19.68 | 20.32 | 18.42 | 630239 | 19.12949462 | CS |
4 | -4.365 | -19.0030474532 | 22.97 | 23 | 18.42 | 819877 | 20.33307726 | CS |
12 | -3.065 | -14.1439778496 | 21.67 | 28.26 | 18.42 | 972257 | 23.47550344 | CS |
26 | -2.425 | -11.5311459819 | 21.03 | 28.26 | 16.52 | 904787 | 21.66946084 | CS |
52 | -24.755 | -57.0917896679 | 43.36 | 59.99 | 16.515 | 1036787 | 27.26763339 | CS |
156 | -55.135 | -74.7694602658 | 73.74 | 81 | 16.515 | 750678 | 36.14242154 | CS |
260 | -140.295 | -88.2913782253 | 158.9 | 193.56 | 16.515 | 742915 | 51.79527154 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions